Zydus Lifesciences Limited — Investor Meet, 24-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Zydus Lifesciences delivered strong FY26 results with consolidated revenue of ₹27,150 Cr (+17% YoY) and EBITDA of ₹8,480 Cr (+20% YoY), achieving 31.2% margins. Q4 also saw healthy growth. For FY27, management forecasts high teens revenue growth and EBITDA margins >24%, despite competition.

The US business anticipates single-digit growth, bolstered by specialty launches and the Assertio oncology acquisition. India continues to outperform the market, driven by innovative biosimilars and strategic Semaglutide partnerships. International and Consumer Wellness segments show robust double-digit expansion. R&D spend remains a priority at ~8%. Management is confident in its strategic pivots, pipeline, and financial health, with net debt to EBITDA at a comfortable 0.5x.